688298 东方生物
已收盘 02-05 15:00:00
资讯
新帖
简况
疫情红利退潮,东方生物狂赚后现三连亏,被诉讼缠身出海遇坎
证券之星 · 02-05 10:22
疫情红利退潮,东方生物狂赚后现三连亏,被诉讼缠身出海遇坎
每周股票复盘:东方生物(688298)预计2025年扣非净利亏损5.58亿元
证券之星 · 02-01
每周股票复盘:东方生物(688298)预计2025年扣非净利亏损5.58亿元
股市必读:东方生物(688298)预计2025年全年归属净利润亏损约5.23亿元
证券之星 · 01-30
股市必读:东方生物(688298)预计2025年全年归属净利润亏损约5.23亿元
东方生物最新公告:2025年预亏5.23亿元
证券之星 · 01-29
东方生物最新公告:2025年预亏5.23亿元
每周股票复盘:东方生物(688298)获多项国内外器械注册证
证券之星 · 01-25
每周股票复盘:东方生物(688298)获多项国内外器械注册证
东方生物(688298)披露获得多项医疗器械注册证,1月23日股价上涨0.87%
证券之星 · 01-23
东方生物(688298)披露获得多项医疗器械注册证,1月23日股价上涨0.87%
每周股票复盘:东方生物(688298)拟终止募投项目补流
证券之星 · 01-18
每周股票复盘:东方生物(688298)拟终止募投项目补流
东方生物股东会通过终止部分募投项目并将剩余资金永久补流议案
中金财经 · 01-14
东方生物股东会通过终止部分募投项目并将剩余资金永久补流议案
东方生物(688298)披露终止部分募投项目并永久补流公告,1月13日股价上涨0.08%
证券之星 · 01-13
东方生物(688298)披露终止部分募投项目并永久补流公告,1月13日股价上涨0.08%
每周股票复盘:东方生物(688298)拟终止募投项目
证券之星 · 01-11
每周股票复盘:东方生物(688298)拟终止募投项目
东方生物拟终止技术研发中心建设项目 剩余募集资金永久补流
中金财经 · 01-06
东方生物拟终止技术研发中心建设项目 剩余募集资金永久补流
东方生物(688298)披露拟终止募投项目并补流,1月5日股价上涨5.12%
证券之星 · 01-05
东方生物(688298)披露拟终止募投项目并补流,1月5日股价上涨5.12%
每周股票复盘:东方生物(688298)终止研发中心项目补流4231万
证券之星 · 2025-12-28
每周股票复盘:东方生物(688298)终止研发中心项目补流4231万
东方生物拟终止部分募投项目并将剩余资金永久补充流动资金
中金财经 · 2025-12-27
东方生物拟终止部分募投项目并将剩余资金永久补充流动资金
东方生物(688298)披露终止部分募投项目并补流,12月26日股价下跌0.58%
证券之星 · 2025-12-26
东方生物(688298)披露终止部分募投项目并补流,12月26日股价下跌0.58%
东方生物(688298)及子公司多款体外诊断试剂获国内外注册证
中金财经 · 2025-12-20
东方生物(688298)及子公司多款体外诊断试剂获国内外注册证
每周股票复盘:东方生物(688298)召开临时股东会并选举独董
证券之星 · 2025-11-23
每周股票复盘:东方生物(688298)召开临时股东会并选举独董
东方生物(688298)披露选举独立董事并调整专门委员会议案获股东会通过,11月20日股价下跌1.58%
证券之星 · 2025-11-20
东方生物(688298)披露选举独立董事并调整专门委员会议案获股东会通过,11月20日股价下跌1.58%
每周股票复盘:东方生物(688298)获多项医疗器械注册证
证券之星 · 2025-11-16
每周股票复盘:东方生物(688298)获多项医疗器械注册证
东方生物(688298)披露获得医疗器械注册证,11月14日股价上涨1.48%
证券之星 · 2025-11-14
东方生物(688298)披露获得医疗器械注册证,11月14日股价上涨1.48%
加载更多
公司概况
公司名称:
浙江东方基因生物制品股份有限公司
所属行业:
医药制造业
上市日期:
2020-02-05
主营业务:
浙江东方基因生物制品股份有限公司的主营业务是体外诊断产品的研发、生产与销售。公司的主要产品是上游的抗原/抗体、引物、探针、微球等生物原料,中游的免疫诊断平台(胶体金、荧光免疫、酶联免疫)、分子诊断平台(PCR核酸+FISH荧光原位杂交)、流式荧光(液态芯片)平台、生化诊断平台相关的诊断试剂以及配套诊断仪器,下游第三方独立检测实验室等构成,以及动物疫苗、动宠物检测试剂等相关动保产品。
发行价格:
21.25
{"stockData":{"symbol":"688298","market":"SH","secType":"STK","nameCN":"东方生物","latestPrice":24.27,"timestamp":1770274800000,"preClose":24.33,"halted":0,"volume":1864271,"delay":0,"changeRate":-0.0025,"floatShares":202000000,"shares":202000000,"eps":-2.3785,"marketStatus":"已收盘","change":-0.06,"latestTime":"02-05 15:00:00","open":24.29,"high":24.45,"low":24.12,"amount":45329900,"amplitude":0.0136,"askPrice":24.27,"askSize":96,"bidPrice":24.26,"bidSize":38,"shortable":0,"etf":0,"ttmEps":-2.3785,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770341400000},"marketStatusCode":5,"adr":0,"adjPreClose":24.33,"symbolType":"stock_kcb","openAndCloseTimeList":[[1770255000000,1770262200000],[1770267600000,1770274800000]],"highLimit":26.76,"lowLimit":21.9,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":201600000,"isCdr":false,"pbRate":0.77,"roa":"--","roe":"--","epsLYR":-2.69,"committee":0.923132,"marketValue":4893000000,"turnoverRate":0.0092,"status":1,"afterMarket":{"amount":0,"volume":0,"close":24.27,"buyVolume":0,"sellVolume":0,"time":1770276837558,"indexStatus":"已收盘 02-05 15:30:00","preClose":24.33},"floatMarketCap":4893000000},"requestUrl":"/m/hq/s/688298","defaultTab":"news","newsList":[{"id":"2609634578","title":"疫情红利退潮,东方生物狂赚后现三连亏,被诉讼缠身出海遇坎","url":"https://stock-news.laohu8.com/highlight/detail?id=2609634578","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609634578?lang=zh_cn&edition=full","pubTime":"2026-02-05 10:22","pubTimestamp":1770258157,"startTime":"0","endTime":"0","summary":"疫情红利消退,业绩三连亏东方生物发布的业绩预告显示,2025年归母净利润预计亏损5.23亿元;扣非后净利润预计亏损5.58亿元。证券之星注意到,随着疫情红利逐步消退,东方生物经营状况急转直下:2023年,公司首次出现亏损,当年归母净利润为-3.98亿元;2024年亏损规模进一步扩大至5.29亿元。FS公司认为,东方生物违反了合同中约定的“禁止规避”条款,与其客户形成合作关系,造成其经济损失。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026020500010723.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688298","BK0239"],"gpt_icon":0},{"id":"2608070319","title":"每周股票复盘:东方生物(688298)预计2025年扣非净利亏损5.58亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608070319","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608070319?lang=zh_cn&edition=full","pubTime":"2026-02-01 03:53","pubTimestamp":1769889187,"startTime":"0","endTime":"0","summary":"东方生物发布业绩预告,预计2025年全年归属净利润亏损约5.23亿元。公司公告汇总浙江东方基因生物制品股份有限公司预计2025年年度实现归属于母公司所有者的净利润为-5.23亿元,扣除非经常性损益后的净利润为-5.58亿元。本期业绩亏损主要由于各产业技术平台战略发展投入较大,汇兑损失增加,利息收入减少,以及计提资产折旧摊销和部分资产减值损失所致。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100001363.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688298"],"gpt_icon":0},{"id":"2607030023","title":"股市必读:东方生物(688298)预计2025年全年归属净利润亏损约5.23亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2607030023","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607030023?lang=zh_cn&edition=full","pubTime":"2026-01-30 02:33","pubTimestamp":1769711590,"startTime":"0","endTime":"0","summary":"来自:东方生物预计2025年年度扣除非经常性损益后的净利润为-5.58亿元,亏损主因包括战略投入加大、汇兑损失增加及资产折旧摊销等。业绩披露要点业绩预告东方生物发布业绩预告,预计2025年全年归属净利润亏损约5.23亿元;扣非后净利润亏损约5.58亿元。本期业绩亏损主要由于各产业技术平台战略发展投入较大,汇兑损失增加,利息收入减少,以及计提资产折旧摊销和部分资产减值损失所致。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000001474.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688298"],"gpt_icon":0},{"id":"2607867700","title":"东方生物最新公告:2025年预亏5.23亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2607867700","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607867700?lang=zh_cn&edition=full","pubTime":"2026-01-29 17:41","pubTimestamp":1769679713,"startTime":"0","endTime":"0","summary":"东方生物(688298.SH)公告称,预计2025年净利润亏损5.23亿元,上年同期亏损5.29亿元。报告期内,因各产业技术平台战略发展,整体培育期间持续投入较大,汇兑损失及利息收入对利润的贡献减少,同时计提资产相关折旧摊销费用,计提部分资产减值损失等原因,使得2025年度净利润亏损。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012900030094.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688298","BK0239"],"gpt_icon":0},{"id":"2606321802","title":"每周股票复盘:东方生物(688298)获多项国内外器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2606321802","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606321802?lang=zh_cn&edition=full","pubTime":"2026-01-25 02:44","pubTimestamp":1769280252,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘,东方生物报收于25.4元,较上周的24.9元上涨2.01%。本周,东方生物1月23日盘中最高价报25.4元。东方生物当前最新总市值51.21亿元,在医疗器械板块市值排名75/127,在两市A股市值排名3517/5182。公司公告汇总浙江东方基因生物制品股份有限公司及控股子公司杭州丹威生物科技有限公司近日获得多项医疗器械注册证。上述产品注册证的取得有助于完善公司产品布局并拓展国内外市场。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012500000861.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688298","BK0239"],"gpt_icon":0},{"id":"2605064704","title":"东方生物(688298)披露获得多项医疗器械注册证,1月23日股价上涨0.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605064704","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605064704?lang=zh_cn&edition=full","pubTime":"2026-01-23 22:47","pubTimestamp":1769179634,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘,东方生物报收于25.4元,较前一交易日上涨0.87%,最新总市值为51.21亿元。该股当日开盘25.18元,最高25.4元,最低25.1元,成交额达5051.29万元,换手率为0.99%。东方生物近日发布《关于自愿披露获得医疗器械注册证的公告》。公告显示,浙江东方基因生物制品股份有限公司及控股子公司杭州丹威生物科技有限公司近日获得多项医疗器械注册证。上述产品注册证的取得有助于完善公司产品布局并拓展国内外市场。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012300043411.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09996","BK1574","159883","688298","BK1100","BK1583","09997","BK1222","BK0239"],"gpt_icon":0},{"id":"2604925872","title":"每周股票复盘:东方生物(688298)拟终止募投项目补流","url":"https://stock-news.laohu8.com/highlight/detail?id=2604925872","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604925872?lang=zh_cn&edition=full","pubTime":"2026-01-18 03:36","pubTimestamp":1768678569,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘,东方生物报收于24.9元,较上周的25.1元下跌0.8%。本周关注点公司公告汇总:东方生物拟终止部分募投项目,将剩余募资永久补流。国浩律师(杭州)事务所对本次会议出具法律意见书,认为会议召集、召开程序合法有效。国浩律师(杭州)事务所出具法律意见书,确认本次股东会的召集、召开程序,出席会议人员资格、召集人资格,会议表决程序及表决结果均符合相关法律法规及公司章程规定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011800001007.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688298"],"gpt_icon":0},{"id":"2603265998","title":"东方生物股东会通过终止部分募投项目并将剩余资金永久补流议案","url":"https://stock-news.laohu8.com/highlight/detail?id=2603265998","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603265998?lang=zh_cn&edition=full","pubTime":"2026-01-14 08:04","pubTimestamp":1768349058,"startTime":"0","endTime":"0","summary":"中访网数据 浙江东方基因生物制品股份有限公司于2026年1月13日以现场结合网络投票方式召开了2026年第一次临时股东会。根据表决结果,该议案获得普通股股东有效表决权股份总数约98.80%的同意票,反对票占比约1.12%,弃权票占比约0.08%。此次决议意味着公司将终止特定的募集资金投资项目,并将该项目剩余的募集资金永久性地用于补充公司日常经营所需的流动资金。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260114/31939258.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688298","BK0239"],"gpt_icon":0},{"id":"2603285638","title":"东方生物(688298)披露终止部分募投项目并永久补流公告,1月13日股价上涨0.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603285638","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603285638?lang=zh_cn&edition=full","pubTime":"2026-01-13 22:39","pubTimestamp":1768315151,"startTime":"0","endTime":"0","summary":"截至2026年1月13日收盘,东方生物报收于25.68元,较前一交易日上涨0.08%,最新总市值为51.77亿元。该股当日开盘25.55元,最高26.12元,最低25.4元,成交额达8480.77万元,换手率为1.63%。近日,浙江东方基因生物制品股份有限公司召开2026年第一次临时股东会,审议通过《关于终止部分募集资金投资项目并将剩余募集资金永久性补充流动资金的议案》。议案获普通决议通过,中小投资者对该议案进行了单独计票。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011300042546.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688298","BK0239"],"gpt_icon":0},{"id":"2602536651","title":"每周股票复盘:东方生物(688298)拟终止募投项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2602536651","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602536651?lang=zh_cn&edition=full","pubTime":"2026-01-11 03:51","pubTimestamp":1768074667,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘,东方生物报收于25.1元,较上周的23.43元上涨7.13%。本周,东方生物1月6日盘中最高价报25.24元。该事项不构成关联交易,保荐机构无异议。本议案已由第三届董事会第十六次会议审议通过,现提请股东会审议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100001194.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688298","BK0239"],"gpt_icon":0},{"id":"2601857305","title":"东方生物拟终止技术研发中心建设项目 剩余募集资金永久补流","url":"https://stock-news.laohu8.com/highlight/detail?id=2601857305","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601857305?lang=zh_cn&edition=full","pubTime":"2026-01-06 10:53","pubTimestamp":1767667993,"startTime":"0","endTime":"0","summary":"中访网数据 浙江东方基因生物制品股份有限公司于2025年12月27日发布公告,拟终止其首次公开发行股份的募集资金投资项目之一“技术研发中心建设项目”。公司表示,该项目新建大楼已竣工,结合当前实际研发情况,暂无继续大额投入研发设备的迫切需求。因此,公司计划将该项目剩余募集资金及利息收入永久性补充流动资金,用于日常经营活动。保荐机构对该事项无异议。此举旨在提高募集资金使用效率,优化公司财务结构。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260106/31918443.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","688298"],"gpt_icon":0},{"id":"2601880333","title":"东方生物(688298)披露拟终止募投项目并补流,1月5日股价上涨5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601880333","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601880333?lang=zh_cn&edition=full","pubTime":"2026-01-05 22:48","pubTimestamp":1767624498,"startTime":"0","endTime":"0","summary":"截至2026年1月5日收盘,东方生物报收于24.63元,较前一交易日上涨5.12%,最新总市值为49.65亿元。该股当日开盘23.46元,最高24.8元,最低23.46元,成交额达7813.74万元,换手率为1.59%。公告显示,公司拟终止首次公开发行股份募集资金投资项目中的“技术研发中心建设项目”。该事项不构成关联交易,保荐机构无异议。本议案已由第三届董事会第十六次会议审议通过,现提请股东会审议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500040586.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688298"],"gpt_icon":0},{"id":"2594242083","title":"每周股票复盘:东方生物(688298)终止研发中心项目补流4231万","url":"https://stock-news.laohu8.com/highlight/detail?id=2594242083","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594242083?lang=zh_cn&edition=full","pubTime":"2025-12-28 04:25","pubTimestamp":1766867111,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘,东方生物报收于24.13元,较上周的24.25元下跌0.49%。浙江东方基因生物制品股份有限公司拟终止首次公开发行股份募集资金投资项目中的“技术研发中心建设项目”,并将该项目剩余募集资金及利息收入永久性补充流动资金,用于公司日常经营活动。浙江东方基因生物制品股份有限公司制定证券投资管理制度,规范公司及子公司的证券投资行为。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800001097.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688298"],"gpt_icon":0},{"id":"2594212468","title":"东方生物拟终止部分募投项目并将剩余资金永久补充流动资金","url":"https://stock-news.laohu8.com/highlight/detail?id=2594212468","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594212468?lang=zh_cn&edition=full","pubTime":"2025-12-27 12:59","pubTimestamp":1766811546,"startTime":"0","endTime":"0","summary":"中访网数据 浙江东方基因生物制品股份有限公司于2025年12月27日发布公告,宣布将于2026年1月13日召开2026年第一次临时股东大会。本次会议的核心议题是审议《关于终止部分募集资金投资项目并将剩余募集资金永久性补充流动资金的议案》。本次议案需对中小投资者的表决情况单独计票。公司董事会已就此议案形成决议,相关公告已依法披露。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251227/31896378.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688298","BK0239"],"gpt_icon":0},{"id":"2594429835","title":"东方生物(688298)披露终止部分募投项目并补流,12月26日股价下跌0.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2594429835","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594429835?lang=zh_cn&edition=full","pubTime":"2025-12-26 17:49","pubTimestamp":1766742543,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘,东方生物报收于24.13元,较前一交易日下跌0.58%,最新总市值为48.65亿元。该股当日开盘24.36元,最高24.36元,最低24.09元,成交额达2753.3万元,换手率为0.56%。根据近日发布的第三届董事会第十六次会议决议公告,浙江东方基因生物制品股份有限公司于2025年12月25日召开会议,审议通过《关于终止部分募集资金投资项目并将剩余募集资金永久性补充流动资金的议案》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122600025960.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688298"],"gpt_icon":0},{"id":"2592114645","title":"东方生物(688298)及子公司多款体外诊断试剂获国内外注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2592114645","media":"中金财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592114645?lang=zh_cn&edition=full","pubTime":"2025-12-20 12:19","pubTimestamp":1766204343,"startTime":"0","endTime":"0","summary":"中访网数据 浙江东方基因生物制品股份有限公司及其全资子公司近期在国内外医疗器械注册方面取得多项进展。在国内,其子公司上海万子健生物科技有限公司的“6项细胞因子检测试剂盒”以及哈尔滨东方基因生物制品有限公司的睾酮、泌乳素、促卵泡生成素、雌二醇等共计7款“时间分辨荧光免疫层析法”检测试剂盒,于2025年12月获得中国国家药品监督管理局颁发的医疗器械注册证,有效期至2030年12月。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251220/31879565.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","688298"],"gpt_icon":0},{"id":"2585810305","title":"每周股票复盘:东方生物(688298)召开临时股东会并选举独董","url":"https://stock-news.laohu8.com/highlight/detail?id=2585810305","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585810305?lang=zh_cn&edition=full","pubTime":"2025-11-23 03:06","pubTimestamp":1763838373,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘,东方生物报收于24.85元,较上周的28.08元下跌11.5%。本周,东方生物11月17日盘中最高价报28.39元。公司公告汇总浙江东方基因生物制品股份有限公司于2025年11月20日召开2025年第二次临时股东会,审议通过《关于选举独立董事并调整专门委员会及委员的议案》。本次会议表决结果为同意99,178,155股,反对818,447股,弃权14,149股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112300000747.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688298","BK0239"],"gpt_icon":0},{"id":"2584213011","title":"东方生物(688298)披露选举独立董事并调整专门委员会议案获股东会通过,11月20日股价下跌1.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584213011","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584213011?lang=zh_cn&edition=full","pubTime":"2025-11-20 22:25","pubTimestamp":1763648722,"startTime":"0","endTime":"0","summary":"截至2025年11月20日收盘,东方生物报收于26.2元,较前一交易日下跌1.58%,最新总市值为52.82亿元。该股当日开盘26.68元,最高26.88元,最低26.08元,成交额达5903.86万元,换手率为1.11%。根据公司近日发布的公告,浙江东方基因生物制品股份有限公司于2025年11月20日召开2025年第二次临时股东会,审议通过了关于选举独立董事并调整专门委员会及委员的议案。议案获得普通决议通过,中小投资者对该议案进行了单独计票。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112000038303.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688298"],"gpt_icon":0},{"id":"2583865189","title":"每周股票复盘:东方生物(688298)获多项医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2583865189","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583865189?lang=zh_cn&edition=full","pubTime":"2025-11-16 03:10","pubTimestamp":1763233818,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘,东方生物报收于28.08元,较上周的26.15元上涨7.38%。本周,东方生物11月12日盘中最高价报28.99元。本周关注点公司公告汇总:东方生物及控股子公司获多项国内及欧盟医疗器械注册证。公司公告汇总浙江东方基因生物制品股份有限公司及控股子公司杭州莱和生物技术有限公司近日取得多项医疗器械注册证。上述产品注册证有效期均为2025年11月3日至2030年11月2日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600000725.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1100","09996","BK1574","BK1583","09997","BK1222","159883","688298","BK0239"],"gpt_icon":0},{"id":"2583502341","title":"东方生物(688298)披露获得医疗器械注册证,11月14日股价上涨1.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583502341","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583502341?lang=zh_cn&edition=full","pubTime":"2025-11-14 22:31","pubTimestamp":1763130661,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘,东方生物报收于28.08元,较前一交易日上涨1.48%,最新总市值为56.61亿元。该股当日开盘27.6元,最高28.53元,最低27.46元,成交额达1.15亿元,换手率为2.03%。公司近日发布公告称,浙江东方基因生物制品股份有限公司及控股子公司杭州莱和生物技术有限公司取得多项医疗器械注册证。上述产品注册证有效期均为2025年11月3日至2030年11月2日。此次取证有助于完善公司在国内外呼吸道检测领域的布局,拓展产品市场。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400041865.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","09996","BK1574","BK0239","BK1100","159883","BK1222","688298","09997"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770313484140,"stockEarnings":[{"period":"1week","weight":-0.0388},{"period":"1month","weight":-0.0253},{"period":"3month","weight":-0.0719},{"period":"6month","weight":-0.1484},{"period":"1year","weight":-0.1798},{"period":"ytd","weight":0.0359}],"compareEarnings":[{"period":"1week","weight":-0.0197},{"period":"1month","weight":-0.0019},{"period":"3month","weight":0.0196},{"period":"6month","weight":0.1213},{"period":"1year","weight":0.2621},{"period":"ytd","weight":0.027}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江东方基因生物制品股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"13289人(较上一季度减少3.93%)","perCapita":"15170股","listingDate":"2020-02-05","address":"浙江省湖州市安吉县递铺街道阳光大道东段3787号","registeredCapital":"20160万元","survey":" 浙江东方基因生物制品股份有限公司的主营业务是体外诊断产品的研发、生产与销售。公司的主要产品是上游的抗原/抗体、引物、探针、微球等生物原料,中游的免疫诊断平台(胶体金、荧光免疫、酶联免疫)、分子诊断平台(PCR核酸+FISH荧光原位杂交)、流式荧光(液态芯片)平台、生化诊断平台相关的诊断试剂以及配套诊断仪器,下游第三方独立检测实验室等构成,以及动物疫苗、动宠物检测试剂等相关动保产品。","listedPrice":21.25},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"东方生物(688298)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供东方生物(688298)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"东方生物,688298,东方生物股票,东方生物股票老虎,东方生物股票老虎国际,东方生物行情,东方生物股票行情,东方生物股价,东方生物股市,东方生物股票价格,东方生物股票交易,东方生物股票购买,东方生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"东方生物(688298)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供东方生物(688298)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}